Skip to main content
Premium Trial:

Request an Annual Quote

Synchron Buys French Biomarker, Dx Services Lab for $6.7M

NEW YORK (GenomeWeb News) - Indian clinical research organization Synchron Research Services has acquired from Parexel a biomarker and bioanalytical research facility based in France for around $6.7 million, Synchron said today.
 
The lab, which is located in Poitiers, France, and was bought by Parexel in 1999, will now be called Synexel Research International. The lab offers singleplexed and multiplexed immunoassay platforms that support early clinical, pre-clinical, and clinical studies, as well as biomarker research programs.
 
Synchron said the lab is GLP Class A certified by Afssaps, France.
 
Ahmedabad-based Synchron said it has agreed to retain all of the staff and management team at the Synexel facility.
 
In addition to the acquisition, Synchron said that Parexel had increased the stake it owns in Synchron from 19.5 percent to 31 percent, but it did not disclose the amount of the investment.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.